Leuprorelin 99% Cas No.53714-56-0
Source: N/A
Specification: ≥99%
CAS No.: 53714-56-0
Molecular Formula: C₅₉H₈₄N₁₆O₁₂
Molecular Weight: 1209.40 g/mol
Test Method: HPLC
Active Ingredient: Gonadotropin-Releasing Hormone (GnRH) Receptor Agonist
Product Characteristics: White to off-white powder or fluffy solid
Packaging: Available in various specifications (mg, g, kg), customizable
Storage Condition: Store in a cool, dry, and well-ventilated place. Keep the container tightly closed.
Shelf Life: 36 months
Declaration of Use: This product is intended for industrial use or scientific research only.
Leuprorelin API | CAS 53714-56-0 | GnRH Agonist
Leuprorelin (also known as Leuprolide) is a highly potent synthetic nonapeptide analog of Gonadotropin-Releasing Hormone (GnRH). Engineered for advanced pharmaceutical research and development, Xi'an Tihealth Biotechnology Co., Ltd. supplies this active pharmaceutical ingredient (API) with an HPLC purity of ≥ 99.0%. Characterized by its profound resistance to enzymatic degradation and prolonged in vivo half-life, our Leuprorelin API is optimized for the formulation of sustained-release depot injections and targeted endocrine therapeutics.
⚠️ REGULATORY COMPLIANCE & RESEARCH USE ONLY (RUO)
Industrial R&D Application: This high-purity Leuprorelin is supplied strictly as a raw material API powder for professional laboratory research, biopharmaceutical development, and formulation trials. It is NOT a finished pharmaceutical drug and is explicitly prohibited for direct administration to humans or animals.
Chemical Profile & Specification Parameters
| Analytical Parameter | Xi'an Tihealth Specification |
|---|---|
| Generic Name | Leuprorelin / Leuprolide |
| CAS Number | 53714-56-0 |
| Molecular Formula | C59H84N16O12 |
| Molecular Weight | 1209.4 g/mol |
| Peptide Purity (HPLC) | ≥ 99.0% |
| Appearance | White to off-white lyophilized powder |
Storage & Handling Protocols: Preserve in tight, light-resistant containers. Store strictly at -20°C in a desiccated environment to maintain peptide bond integrity. Allow the sealed vial to reach room temperature before opening to prevent condensation.
Pharmacodynamics & Mechanism of Action
Leuprorelin exerts its pharmacological action through a biphasic modulation of the hypothalamic-pituitary-gonadal (HPG) axis. It binds with high affinity to GnRH receptors on the membranes of pituitary gonadotrope cells:
- Initial Stimulatory Phase: Acute administration stimulates the anterior pituitary gland, causing a transient surge in the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), leading to a temporary increase in gonadal steroidogenesis.
- Sustained Suppressive Phase: Continuous receptor occupancy by this degradation-resistant nonapeptide disrupts the physiological pulsatile signaling of endogenous GnRH. This induces rapid receptor desensitization and internalization.
- Castration-Level Suppression: The resulting disconnection of the HPG axis leads to a profound and sustained suppression of LH and FSH secretion, ultimately reducing serum testosterone and estradiol to castration levels. This mechanism is entirely reversible upon cessation of exposure.
Therapeutic R&D Applications
Supplied strictly for pharmaceutical manufacturing and formulation development, Leuprorelin API is foundational for medications targeting hormone-dependent pathologies:
- Oncology: Core API for depot formulations intended for the palliative treatment of advanced prostate cancer and the management of hormone receptor-positive breast cancer in pre/perimenopausal demographics.
- Gynecological Disorders: Investigated for pre-operative treatment of uterine leiomyomas (fibroids) to reduce fibroid volume, and for the systemic symptom management of endometriosis.
- Pediatric Endocrinology: Utilized in R&D for protocols designed to arrest the premature progression of Central Precocious Puberty (CPP).
Technical & Procurement FAQ
Yes. Our Leuprorelin API is engineered with precise particle size distribution and exceptionally low moisture content, making it highly compatible with poly(lactic-co-glycolic acid) (PLGA) encapsulation technologies for 1-month, 3-month, or 6-month sustained-release injectables.
Leuprorelin is standardly supplied as Leuprorelin Acetate to ensure optimal solubility and stability during the formulation process. Please specify if your R&D requires a different counter-ion during the inquiry phase.
Every batch released by Xi'an Tihealth is accompanied by a full analytical dossier, including the Certificate of Analysis (COA), explicit HPLC purity chromatograms, Electrospray Ionization Mass Spectrometry (ESI-MS) verification, and residual solvent testing compliant with international ICH Q3C guidelines.
Xi'an Tihealth Biotechnology Co., Ltd. Statement: Pharmaceutical API intended strictly for laboratory analysis and developmental pipeline research. Not for direct clinical administration.
Hot Tags: leuprorelin 99% cas no.53714-56-0, China leuprorelin 99% cas no.53714-56-0 manufacturers, suppliers, factory, tranexamic powder
You Might Also Like
Send Inquiry